Related references
Note: Only part of the references are listed.Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry
Parichoy Pal Choudhury et al.
BREAST CANCER RESEARCH (2021)
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
Jack Cuzick et al.
LANCET (2020)
Costs of Early Invasive Breast Cancer in England Using National Patient-Level Data
Li Sun et al.
VALUE IN HEALTH (2020)
Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
Adam R. Brentnall et al.
BREAST CANCER RESEARCH (2020)
Chemoprevention Uptake for Breast Cancer Risk Reduction Varies by Risk Factor
Meghan R. Flanagan et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
Andrea DeCensi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Statin Use in Primary Prevention of Atherosclerotic Cardiovascular Disease According to 5 Major Guidelines for Sensitivity, Specificity, and Number Needed to Treat
Martin Bodtker Mortensen et al.
JAMA CARDIOLOGY (2019)
Uptake of breast cancer preventive therapy in the UK: results from a multicentre prospective survey and qualitative interviews
Julia Hackett et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 2015
Katrina F. Brown et al.
BRITISH JOURNAL OF CANCER (2018)
Prescribing tamoxifen in primary care for the prevention of breast cancer: a national online survey of GPs' attitudes
Samuel G. Smith et al.
BRITISH JOURNAL OF GENERAL PRACTICE (2017)
Cancer incidence and mortality projections in the UK until 2035
C. R. Smittenaar et al.
BRITISH JOURNAL OF CANCER (2016)
Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial
Jack Cuzick et al.
LANCET ONCOLOGY (2015)
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
Jack Cuzick et al.
LANCET (2013)
Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010
Erika A. Waters et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Chernoprevention: Drug pricing and mortality - The case of tamoxifien
Joy Melnikow et al.
CANCER (2006)
A breast cancer prediction model incorporating familial and personal risk factors
J Tyrer et al.
STATISTICS IN MEDICINE (2004)
Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention
AN Freedman et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Share Paper
